Daiichi Sankyo discovers and develops human medicines, generic pharmaceuticals, over-the-counter and animal health products.
Business Model:
Revenue: $9.1B
Employees: 10,001-999,999
Daiichi Sankyo was acquired by
Taiyo Holdings Co..
The acquisition happend on 2019-10-01.
Details of the transaction were not public
Address: 3-5-1, Nihonbashi-honcho
City: Chuo-ku
State: tōkyō prefecture
Zip: 103-8426
Country: JP
Daiichi Sankyo discovers and develops human medicines, generic pharmaceuticals, over-the-counter and animal health products.
Contact Phone:
Contact Email:
Listed Exchange:
Tokyo Stock Exchange
IPO Date:
9/28/2005
Ticker Symbol:
4568
Opened: -/share
EBITDA | - |
Total Cash | - |
Total Debt | - |
Total Revenue | - |
Total Profit (Gross) | - |
PE Ratio | - |
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
1/2012 | Coherus Biosciences | Series B | 0 |
10/2005 | SymBio Pharmaceuticals | Series A | - |
8/2017 | Cuorips, Inc. | Seed Round | 0 |
2/2013 | Orphan Disease Treatment Institute | Pre Seed Round | 0 |
7/2018 | Cuorips, Inc. | Venture Round | 0 |
7/2018 | Cuorips, Inc. | Venture Round | 0 |
8/2017 | Cuorips, Inc. | Seed Round | 0 |
2/2013 | Orphan Disease Treatment Institute | Pre Seed Round | 0 |
1/2012 | Coherus Biosciences | Series B | 0 |
10/2005 | SymBio Pharmaceuticals | Series A | - |
Announced Date | Transaction | Number of Investors | Money Raised | Lead Investors |
---|
Announced Date | Name | Price |
---|---|---|
10/2015 | Im Co., Ltd. | |
9/2014 | Ambit Biosciences | |
2/2011 | Plexxikon | |
11/2008 | Ranbaxy Laboratories | |
5/2008 | U3 Pharma |
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|